500 to 2,000 mg daily in one or two doses. Your doctor should order periodic blood and urine tests to check for unwanted effects. Before taking any DMARD, tell your doctor if you are planning to ...

† One patient had MMF as an initial treatment. ‡ In the study TAC and MMF were used alone or in combination. §In total, 17 patients were initially treated with MMF and steroids. ¶ Females ...

Early diagnosis and treatment of generalized myasthenia gravis (MG) are important to achieve symptomatic control and limit ...

Patients with NMOSD treated with rituximab and mycophenolate mofetil had a significantly lower relapse risk than patients given tacrolimus during the first year following immunosuppressive therapy.

The data discussed earlier indicate that MMF may have value as an alternative treatment for AIH patients who do not respond to standard treatment. However, more data are required. Randomized ...

Background Long-term immunosuppressive treatment does not efficiently prevent relapses of lupus nephritis (LN). This investigator-initiated randomised trial tested whether mycophenolate mofetil (MMF) ...

Belimumab, a monoclonal antibody, added to standard therapy may treat a broader range of patients with lupus nephritis than previously appreciated.

Current treatments have limitations including relapse, highlighting the need for effective maintenance therapy. This study evaluates the efficacy and safety of mycophenolate mofetil (MMF) as long-term ...

Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der Technischen Universität, Fetscherstrasse 74, D-01307 Dresden, Germany, and Analyticon AG, Hermannswerder, Haus 17, ...

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis ...

The EULAR updated their recommendations for antirheumatic drug use among patients with RMDs during pregnancy and fertility ...

To better compare belimumab’s efficacy with results from phase 3 trials of obinutuzumab, investigators conducted a post hoc analysis of patients with active proliferative lupus nephritis in the MMF ...